SANTA CLARA, Calif. XenoPort, Inc. today announced positive results from a Phase 1 clinical trial of XP21279, a Transported Prodrug of levodopa, or L-Dopa.
XenoPort announces positive results of a Phase 1 clinical trial of XP21279